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Docetaxel (Dtx) chemotherapy is the optional treatment in patients with hormone-refractory 
metastatic prostate cancer, and Dtx-loaded polymeric nanoparticles (NPs) have the potential to 
induce durable clinical responses. However, alternative formulations are needed to overcome the 
serious side effects, also due to the adjuvant used, and to improve the clinical efficacy of the drug.  
In the present study, two novel biodegradable block-copolymers, poly(lactide-co-caprolactone) 
(PLA-PCL) and poly(lactide-co-caprolactone-co-glycolide) (PLGA-PCL), were explored for the 
formulation of Dtx-loaded NPs and compared with PLA- and PLGA-NPs. The nanosystems were 
prepared by an original nanoprecipitation method, using Pluronic F-127 as surfactant agent, and 
were characterized in terms of morphology, size distribution, encapsulation efficiency, crystalline 
structure, and in vitro release. To evaluate the potential anticancer efficacy of a nanoparticulate 
system, in vitro cytotoxicity studies on human prostate cancer cell line (PC3) were carried out. NPs 
were found to be of spherical shape with an average diameter in the range of 100 to 200 nm and a 
unimodal particle size distribution. Dtx was incorporated into the PLGA-PCL NPs with higher 
(p < 0.05) encapsulation efficiency than that of other polymers. Differential scanning calorimetry 
suggested that Dtx was molecularly dispersed in the polymeric matrices. In vitro drug release study 
showed that release profiles of Dtx varied on the bases of characteristics of polymers used for 
formulation. PLA-PCL and PLGA-PCL drug loaded NPs shared an overlapping release profiles, 
and are able to release about 90% of drug within 6 h, when compared with PLA- and PLGA-NPs. 
Moreover, cytotoxicity studies demonstrated advantages of the Dtx-loaded PLGA-PCL NPs over 
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pure Dtx in both time- and concentration-dependent manner. In particular, an increase of 20% of 
PC3 growth inhibition was determined by PLGA-PCL NPs with respect to free drug after 72 h 
incubation and at all tested Dtx concentration. In summary, PLGA-PCL copolymer may be 
considered as an attractive and promising polymeric material for the formulation of Dtx NPs as 
delivery system for prostate cancer treatment, and can also be pursued as a validated system in a 
more large context. 
 
Introduction 
Prostate cancer (PCa) is the most common male malignancy and the second leading cause of cancer 
death in Western industrialized countries [1]. The PCa progression does not only mean distant 
metastases but also development of hormone independence of its cells [2]. 
Docetaxel (Dtx)-based regimen is recommended as optional treatment in patients with hormone-
refractory metastatic PCa, showing effective on locally advanced PCa and increasing overall 
survival [3]. Despite the recently reported promising outcome of Dtx, this drug is associated with 
systemic toxicity that limits the dose and duration of therapy, particularly in elderly patients. 
Adverse effects of Dtx treatment include hypersensitivity reactions, bone marrow suppression, 
cutaneous reactions, fluid retention, peripheral neuropathy, alopecia, cardiac disorders, and 
tiredness [4]. Moreover, to facilitate its clinical use, the Dtx poor water solubility requires a specific 
solvent system, such as ethanol/Tween 80 solution, which causes hypersensitivity reaction, reduced 
uptake by tumor tissue and increased exposure to other body compartments [5]. 
Therefore, alternative Dtx formulations are needed and nanoparticles (NPs)-based drug delivery 
systems are of special interest in addressing the major side effects of anticancer drug. 
Recently, a number of polymers have been investigated for formulating biodegradable Dtx-loaded 
NPs for cancer chemotherapy. The most widely used class of biocompatible and biodegradable 
polymers, approved by Food and Drug Administration (FDA), is that of aliphatic polyesters, 
including poly(lactic acid) (PLA), poly(glycolic acid) (PLGA), and their copolymers [6]. 
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However, these polymers are characterized by a high hydrophobicity and slow degradation rate that 
can represent in some cases a disadvantage for their use as drug carriers [7]. 
In the family of polyesters, polycaprolactone (PCL) shows an excellent biocompatibility and rapid 
degradability, good miscibility with a variety of polymers and great permeability, which make it a 
suitable candidate for drug carrier [8]. 
The methods for the preparation of NPs from the preformed polymers include nanoprecipitation, 
emulsification/solvent evaporation, emulsification/solvent diffusion, and salting out [9]. As for the 
nanoprecipitation, the particle formation is based on precipitation and subsequent solidification of 
the polymer at the interface between a solvent and a non-solvent [10]. Usually, surfactants or 
stabilizers are included in the process to modify the size and the surface properties, and to ensure 
the stability of the NP dispersion [9]. The most popular stabilizer for the production of PLGA-based 
NPs is poly(vinyl alcohol) (PVA). However, it has been found that residual PVA, which is very 
difficult to remove from the particles’ surface, causes relatively lower cellular uptake, thus resulting 
not satisfactorily biocompatible for the human body [11]. Therefore, other surfactants could be 
considered as valuable alternatives to PVA. Poloxamer, a block copolymer of poly(ethylene oxide)–
poly(propylene oxide)–poly(ethylene oxide), commercially known as Pluronic, is another promising 
surface active agent approved by FDA for clinical use [12]. Additionally, several evidence 
demonstrated that poloxamers interact with multidrug-resistant tumors, resulting in a drastic 
sensitization of these tumors with respect to various anticancer agents [13, 14]. 
The present work is aimed at investigating the influence of two previously unexplored 
biodegradable block-copolymers, such as poly(D,L-lactide-co-caprolactone) (PLA-PCL) and poly(L-
lactide-co-caprolactone-co-glycolide) (PLGA-PCL), on the physicochemical and pharmaceutical 
properties of novel Dtx-loaded NPs, using PLA- and PLGA-NPs as comparison. The designed 
nanosystems were obtained by a modified nanoprecipitation technique, using Pluronic F-127 
instead of PVA as stabilizing agent. The NPs were characterized in terms of morphology, 
encapsulation efficiency and crystalline structure, and in vitro release kinetics. Moreover, the 
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antiproliferative efficacy of the most promising nanoparticulate prototype was assessed by in vitro 
cytotoxicity assay toward a human prostate cancer cell line (PC3).  
 
Materials and methods 
Materials 
Poly(D,L-lactide) (PLA) (inherent viscosity 0.55 to 0.75 dl/g in chloroform), poly(D,L-lactide-co-
glycolide) (PLGA) (lactide:glycolide 50:50 molar ratio, inherent viscosity 0.55 to 0.75 dl/g in 
hexafluoroisopropanol) with esters end groups were purchased from Lactel Absorbable Polymers 
(Pelham, AL, USA). Poly(L-lactide-co-caprolactone-co-glycolide) (PLGA-PCL) (L-
lactide:glycolide:caprolactone 70:10:20 molar ratio, inherent viscosity 1.30 dl/g, in chloroform) was 
obtained from Sigma-Aldrich (Steinheim, Germany). Poly(L-lactide-co-caprolactone) (PLA-PCL) 
(lactide:caprolactone 70:30 molar ratio) was kindly provided from Purac Biomaterials (Gorinchen, 
Netherlands). Pluronic® F-127 was obtained from Sigma-Aldrich (Steinheim, Germany). Docetaxel 
(purity 99%) was supplied by ChemieTek (Indianapolis, IN, USA). All other chemicals were 
analytical grade and were used without further purification. 
 
Formulation of nanoparticles 
Drug-loaded NPs were prepared by a novel nanoprecipitation method. Briefly, about 100 mg of 
polymer and drug (1%, w/w) were dissolved in 6 ml of acetonitrile. The organic solution was then 
added dropwise under stirring to an aqueous solution of Pluronic F-127 (1% w/v, 30 ml). The milky 
colloidal suspension was evaporated at room temperature to remove the organic solvent. The 
suspension was centrifuged at 13,000 rpm for 10 min to separate the NPs from the unencapsulated 
drug and residual Pluronic. The pellet was washed thrice with ultrapure water. Drug-free NPs were 
produced in a similar manner. The obtained NP suspension was used immediately for assay or 




Characterization of NPs 
Particle size and size distribution 
Mean diameter and size distribution of the NPs were measured by photon correlation spectroscopy 
with Coulter N4 plus particle size analyzer (Beckman Coulter, Fullerton, CA, USA). The samples 
were diluted with deionized water and sonicated for 5 min before measurement. Each analysis was 
carried out in triplicate. 
 
Surface morphology 
The morphological examination of NPs was performed by scanning electron microscopy (SEM) 
(model DSM 962; Carl Zeiss Inc., Oberkochen, German). A drop of NPs suspension was placed on 
a glass cover slide and dried under vacuum for 12 h. After that, the slides were mounted on 
aluminum stub and the samples were then analyzed at 20 kV acceleration voltage after gold 
sputtering, under an argon atmosphere. 
 
Encapsulation efficiency and yield of production 
To determine the drug loading, an aliquot of NPs (1.0 mg) was dissolved in 0.25 ml of 
acetonitrile/water (50/50, v/v) solution. Samples were centrifuged and the drug content in the 
supernatant was analyzed by HPLC using the method previously reported [15]. The equipment 
consisted of an HPLC system including an autosampler and a diode array detector (HP 1200, 
Agilent Technologies, Santa Clara, CA, USA). The chromatographic separation was performed at 
room temperature using a Jupiter C18 column (250 mm × 2.0 mm, 5 µm pore size, Phenomenex) 
with a flow rate of 0.2 ml/min. Twenty microlitres of samples or calibration standards were injected 
into the column and eluted with a solution of acetonitrile/water solution (50/50, v/v). Detection was 
carried out by monitoring the absorbance signals at 227 nm. The elution period was 25 min and the 
retention time of Dtx was about 9 min. HPLC was calibrated with standard solutions of 5 to 
50 µg/ml of Dtx (correlation coefficient of R2 = 0.9999). 
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The drug encapsulation efficiency (EE%) was calculated as the ratio between the amount of Dtx 
encapsulated in NPs and the weight of drug used for NP preparation.  
The lyophilized NPs from each formulation were weighed and the respective percentage yield of 
production was calculated as the ratio between the amount of NPs weight obtained and the total 
weight of solid materials used for the preparations. 
 
Differential scanning calorimetry (DSC) 
DSC scans of empty and drug-loaded NPs were performed on a DSC Q100 V 9.0 calorimeter (TA 
Instrument, New Castle, USA). Indium was used to calibrate the instrument. The thermograms of 
samples were obtained at a scanning rate of 10°C/min in 30 to 200°C temperature range and 
performed under an Ar purge (50 ml/min). The thermal measurements were carried out on pure Dtx, 
on freeze-dried empty and drug-loaded NPs.  
 
In vitro drug release  
For the in vitro release studies, about 10 mg of Dtx-NPs were suspended in 2.0 ml of release 
medium (phosphate buffer solution of pH 7.4 containing 0.1% w/v Tween 80). The tubes were then 
incubated at 37°C and shaken horizontally at 200 rpm (Thermomixer HLC BioTech, Bovenden, 
Germany). At predetermined time intervals, the tubes were centrifuged at 13,000 rpm for 10 min 
and 1.0 ml aliquots of medium were taken from supernatant and replaced with fresh solution. The 
collected samples were extracted with 0.2 ml dichloromethane, evaporated by nitrogen stream, and 
reconstituted in 100 µl mobile phase.  
The concentration of Dtx released from the NPs was determined by HPLC assay as described above 
and corrected for the dilution due to the addition of fresh medium. 
 
In vitro cytotoxicity assay 
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With respect to particle size, encapsulation efficiency, and yield of production results, the PLGA-
PCL Dtx-loaded NPs were selected for the in vitro cytotoxicity studies. A batch of empty PLGA-
PCL NPs was used as comparison. 
Cancer cell viability of the drug-loaded NPs was evaluated by MTT assay. Hundred microliters of 
PC3 cells were seeded in 96-well plates (Costar, IL, USA) at the density of 5,000 viable cells/well 
and allowed to adhere for 24 h.  
The cells were incubated with free Dtx, Dtx-loaded NP suspension at 0.05, 0.5, 5.0 µg/ml 
equivalent Dtx concentrations, and empty NPs with the same NP concentrations, for 24, 48, and 
72 h, respectively. The selected concentrations were in the range which corresponds to plasma 
levels of the drug achievable in humans [16]. At designated time intervals, the medium was 
removed, and the wells were washed twice with PBS. Ten microliters of 3-(4,5-dimethyl-thiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) solution were added to each well of the plate and 
incubated for another 1 to 4 h. The absorbance was measured at 560 nm using a microplate reader. 
Cell viability was calculated by the following equation:  
 
Cell viability (%) = (Abssample/Abscontrol) × 100, 
 
where Abssample is the absorbance of the cells incubated with the NP suspension, and Abscontrol is the 
absorbance of the cells incubated with the culture medium only (positive control). All experiments 
were repeated thrice. 
 
Statistical methodology 
The data are expressed as mean ± standard deviation (S.D.). The significance of differences was 
assessed by one-way analysis of variance (ANOVA) (Origin®, version 7.0 SR0, OriginLab 




Results and discussion 
Characterization of NPs 
Size, drug entrapment efficiency, and yields of production 
The nanoprecipitation method described here appeared to be a suitable technique to formulate Dtx-
loaded NPs based on PLA and PLGA and their poly-caprolactone copolymers. The preparation was 
carried out by using a polymer concentration in organic phase of 3.3 mg/ml and a solvent:Pluronic® 
F-127 solution ratio of 1:5. Acetonitrile was selected as organic phase for the capability to 
solubilize the polymers and drug and its good water miscibility, that allows a fine polymer 
dispersion into water. 
Moreover, although the most commonly used PVA emulsifier can make uniform particles with 
small size, it has been recently demonstrated that it can form an interconnected network with the 
PLGA polymer at the interface that would compromise the good redispersibility of NPs [11]. 
Additionally, the residual PVA associated with the surface of NPs would influence their physical 
properties and cellular uptake. Therefore, due to the above reasons, PVA was conveniently replaced 
with Pluronic in the current study. 
The prepared NPs were characterized in terms of particle size and size distribution, morphology, 
encapsulation efficiency, and yield of production. The effect of different polymers on the 
characteristics of NPs is summarized in Table 1. 
All NP batches showed a particle diameter ranging from 100 to 200 nm, suitable to obtain an 
effective intracellular uptake [17]. NPs formulated with PLA-PCL polymer showed a significantly 
larger (p < 0.05) mean diameter (195 nm) than that of the PLGA- and PLGA-PCL-Dtx-loaded NPs 
(107 and 115 nm, respectively). As depicted in Figure 1, in all cases, the NP dispersions exhibit a 
unimodal particle size distribution, as also confirmed by the obtained low polydispersity indexes 
(PDI < 0.31), typical of monodispersed systems. This suggests that the presence of Pluronic F127 
can promote the formation of very homogeneous NP dispersions. 
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As far as the drug entrapment efficiency (EE) is concerned, from drug content analysis no 
significant differences were found for the batches based on PLA and PLGA polymers (38 and 35%, 
respectively). On the other hand, relevant differences are obtained for NPs formulated with both 
copolymers containing PCL. The PLGA-PCL NPs exhibited significantly (p < 0.05) higher drug 
encapsulation efficiency (47%) compared with other formulations. 
This finding can be ascribed to the presence of three polymers, PLA, PLGA, and PCL, which are 
able to generate a polymer network characterized by a greatly irregular and disordered crystalline 
structure, which may consequently promote the accommodation of the drug molecules. 
Conversely, the lower percentages of encapsulation efficiency and NP yield obtained with PLA-
PCL copolymer might be explained with a partial and fast precipitation of polymer that occurs after 
addition of organic phase to surfactant solution. Yields of production ranged between 52 and 84%, 
with the highest values for NPs based on PLGA-PCL copolymers. 
Furthermore, the size and particle size distribution of unloaded NPs were similar to the 
corresponding loaded batches, thus indicating that the presence of the drug did not influence these 
characteristics (data not shown). 
 
Surface morphology 
The morphology of NPs was investigated by SEM analysis. As displayed in Figure 2, all batches of 
NPs showed a spherical shape with a smooth surface, without any particle aggregation. 
The partial fusion detected in some NP samples takes place during the analysis, where many NPs 
congregate together. Due to presence of the drug, no difference in the morphological properties of 
NPs drug was observed due to the presence of the drug. 
 
Differential scanning calorimetry (DSC) 
The physical state of Dtx inside the NPs was characterized by analysis of the DSC curves. The pure 
drug shows a characteristic endothermic peak that corresponds to melting at 168°C, indicating a 
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crystalline nature (Figure 3). The comparison between DSC thermograms of drug with unloaded 
and loaded NPs formulated with different polymers showed similar behaviors. 
In all cases, the DSC scans revealed that Dtx melting peak totally disappeared in the calorimetric 
curve of loaded NPs, thus evidencing the absence of crystalline drug in the samples. These results 
suggested that the nanoencapsulation inhibited the crystallization of Dtx during NPs formation. 
Thus, it can be assumed that Dtx was present in the NPs either in an amorphous or disordered 
crystalline phase or in the solid solution state [6]. 
Meanwhile, the loaded systems exhibited the same endothermic events (at 58°C for PLA, 52°C for 
PLGA, 54°C for PLA-PCL, and 50 and 113°C for PLGA-PCL) of the corresponding unloaded NPs, 
referring to melting temperature (Tm) of polymers (Figure 3a to d), suggesting that the 
nanoencapsulation procedure did not affect the polymer structure.  
 
In vitro drug release  
The cumulative percentages of Dtx released from NPs based on different polymers as a function of 
time are reported in Figure 4. All formulations are characterized by similar release profiles, but the 
release rate is strongly affected by the properties of the polymer matrix. In particular, PLA-based 
NPs are characterized by the slower release (only about 60% of Dtx is released within 6 h) that can 
be attributed to the stronger hydrophobic interaction between hydrophobic domain of PLA and 
drug. Due to the presence of the hydrophilic glycolide units into the PLA polymer (50:50 molar 
ratio), in the case of NPs formulated with PLGA a completed dissolution of Dtx is achieved within 
the first 2 hof the test. In fact, the higher hydrophilicity of copolymer improved the water 
permeability into NPs with a more rapid drug diffusion as well as a faster degradation of the 
polymer [8]. As for PCL copolymers, the diffusion rate of drug from PLA-PCL NPs is higher at the 
first 2 h and levelled off after 3 h of the test, thus resulting almost superimposed to those of PLGA-
PCL formulations. These results can be related to the similar composition of PLA-PCL and PLGA-
PCL copolymers containing a lactide:caprolactone 70:30 and lactide:glycolide:caprolactone 
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70:10:20 molar ratio, respectively. Moreover, with respect to PLGA, a significant retard on 
dissolution rate of Dtx from PLGA-PCL NPs alone was obtained, whereas an opposite effect is 
observed in the case of PLA-PCL copolymer compared to PLA-NPs. Furthermore, with respect to 
PLA homopolymer, the more hydrophilic block of caprolactone of PLA-PCL copolymer-based NPs 
leads to a significant improvement of Dtx released (85%, during the 6 h). A complete release of Dtx 
is obtained for all samples after 24 h of the test. 
In order to investigate the kinetic modeling of drug release from NPs, the dissolution profiles were 
fitted to zero order (Q = k0 ⋅ t); first order (ln (100 − Q) = ln Q0 – k1 ⋅ t), Higuchi (Q = kH ⋅ t1/2), and 
Korsmeyer–Peppas models [18]. 
Table 2 shows the correlation coefficient (r2) used as an indicator of the best fitting of the models 
considered for different Dtx-NPs batches. The r2 values for first order kinetics of different 
polymeric NPs (ranging between 0.8830 and 0.9921) were greater than that of Zero order and 
corresponded to that of the Higuchi’s square root of time (ranged between 0.8182 and 0.9813). 
Besides, to understand the drug release mechanism, the first 60% drug release data was fitted to 
Korsmeyer–Peppas exponential model Mt/M∞ = Ktn , where Mt/M∞ is fraction of drug released after 
time ‘t’ and ‘K’ is kinetic constant and ‘n’ is release exponent, which characterizes the different 
drug release mechanism [19]. Based on various mathematical models, the magnitude of the release 
exponent ‘n’ indicates the release mechanism (Fickian diffusion, case II transport, or anomalous 
transport). The limits considered were n ≤ 0.43 (for a classical Fickian diffusion-controlled drug 
release) and n = 0.85 (indicates a case II relaxational release transport; non-Fickian, zero-order 
release). Values of n between 0.43 and 0.85 can be regarded as an indicator of both phenomena 
(drug diffusion in the hydrated matrix and the polymer relaxation) usually called anomalous 
transport [19]. In all formulations, n values ranged from 0.5141 to 0.7842, suggesting an anomalous 
or non-Fickian diffusion, which is related to combination of both diffusion of the drug and 




In vitro cytotoxicity assay 
The in vitro cytotoxicity of Dtx both as free drug and loaded into PLGA-PCL NPs, at the same drug 
equivalent concentration of 0.05, 0.5, and 5.0 µg/ml, was evaluated by the MTT assay using PC3 as 
model prostate cancer cell line. Untreated PC3 cells as well as cells treated with empty PLGA-PCL 
NPs, with the same polymer content of that of the drug-loaded nanosystems, were used as 
comparison. 
Figure 5 shows the viability of PC3 cancer cells, cultured with unloaded PLGA-PCL NPs, and Dtx-
loaded PLGA-PCL NPs, after incubation for 24 h (a), 48  (b), and 72 h (c), in comparison with that 
of pure drug at 0.05, 0.5, and 5.0 µg/ml equivalent Dtx concentrations. 
Since no significant influence on cell viability was detected, drug-free NPs appeared nearly non-
toxic to PC3 cells, even at a high NP concentration, thus confirming the good biocompatibility of 
PLGA-PCL copolymer [20]. 
On the whole, the results clearly demonstrated that Dtx formulated in PLGA-PCL NPs resulted 
more effective against cancer cells than free Dtx. Both the dose exposure and the incubation time 
played a major role in the cell toxicity of Dtx. 
In particular, after 24 h incubation, the PC3 cell viability was decreased to about 65, 55, and 40% 
for PLGA-PCL NPs at 0.05, 0.5, and 5.0 µg/ml drug concentration, respectively, corresponding to 
an increase in cytotoxicity of 25% (p < 0.05) compared with that of free Dtx.  
After 48 h incubation, the cytotoxicity was increased about 55, 60, and 70% for the PLGA-PCL-Dtx 
NPs and 25, 35, and 45% for free drug, respectively.  
The more marked inhibition of cell growth was obtained for longer incubation period (72 h); at all 
tested Dtx concentration, PLGA-PCL NPs determined a significant (p < 0.05) increased of PC3 
growth inhibition (about 20%) with respect to free drug. With an approximately 85% cell viability 
reduction, the strongest cytotoxic effect was achieved with NPs at 5.0 µg/ml Dtx concentration.  
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This finding is related with the mechanism of action of Dtx, which requires cell division to operate. 
In fact, for longer incubation periods, a larger number of cells enter G2 and M cell cycle phases, 
where Dtx selectively works [21]. 
According to literature data, the higher cytotoxicity of the drug formulated into NPs can be 
attributed to the combination of different but not exclusive mechanisms. In fact, the NPs were 
adsorbed on the cell surface leading to an increase in drug concentration near the cell membrane, 
thus generating a concentration gradient that promotes the drug influx into the cell [16]. Besides, 
while part of free Dtx molecules, transported into the cytoplasm by a passive diffusion, were 
transported out by P-glycoprotein (P-gp) pumps, NPs are taken up by cells through an endocytosis 
pathway, thus resulting in a higher cellular uptake of the entrapped drug [22], thereby enabling 
them to escape from the effect of P-gp pumps. Moreover, intracellular delivery of Dtx NPs allows a 
drug accumulation near the site of action [23]. 
 
Conclusions 
In this work, poly(lactide-co-caprolactone) and poly(lactide-co-caprolactone-co-glycolide) 
copolymers were successfully employed for the first time for the nanoencapsulation of Dtx, by 
using a modified nanoprecipitation method. Among the investigated copolymers, PLGA-PCL 
resulted more effective than PLA-PCL-NPs to achieve NPs with small size, uniform distribution, 
and higher encapsulation efficiency. The in vitro studies proved an increased antiproliferative 
efficacy of PLGA-PCL-Dtx NPs compared with free Dtx, in a dose- and time-dependent manner, 
against PC3 cells. 
In conclusion, the PLGA-PCL copolymer can be considered as alternative and promising 
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Figure 1 Particles size distribution of PLA-Dtx (a), PLGA-Dtx (b), PLA-PCL-Dtx, (c) and 
PLGA-PCL-Dtx-loaded NPs (d). 
 
Figure 2 Scanning electron microscopic images of PLA-Dtx (a), PLGA-Dtx (b), PLA-PCL-Dtx 
(c), and PLGA-PCL-Dtx-loaded NPs (d). 
 
Figure 3 DSC thermograms of pure Dtx compared with unloaded and loaded PLA (a), PLGA 
(b), PLA-PCL (c), and PLGA-PCL NPs (d). 
 
Figure 4 In vitro release profiles of Dtx-loaded PLA, PLGA, PLA-PCL, and PLGA-PCL NPs. 
 
Figure 5 Viability of PC3 cells cultured with drug-free nanoparticles (NP), docetaxel-loaded 
PLGA-PCL NPs (NP-Dtx) after 24 h (a), 48 h (b) and 72 h (c), in comparison with that of pure 
drug (Dtx) at the same dose (n = 3).  







Table 1 The effect of the different type of polymers on characteristic of NPs. 
Polymeric NPs Size (nm) PDI EE (%) YP (%) 
PLA 146.3 ± 23.5 0.198 ± 0.03 37.8 ± 3.0 51.9 ± 1.4 
PLGA 106.7 ± 13.5 0.108 ± 0.04 35.2 ± 2.6 68.2 ± 2.7 
PLA-PCL 194.8 ± 31.2 0.308 ± 0.08 19.7 ± 1.4 36.8 ± 1.6 
PLGA-PCL 114.8 ± 15.4 0.258 ± 0.07 47.2 ± 3.8 83.9 ± 3.3 
Data are shown as mean ± S.D., obtained from three formulations. PDI, polydispersity index; EE, 
encapsulation efficiency; YP, yield of production 
 
Table 2 Correlation coefficients (r2) and release exponent (n) of kinetic data analysis of Dtx 
release from different polymeric NPs. 
Koresmeyer–Peppas 
Polymeric NPs Zero order r2 First order r2 Higuchi r2 
r2 n 
PLA 0.8875 0.9481 0.9813 0.9962 0.5141 
PLGA 0.6295 0.8830 0.8182 0.9942 0.6706 
PLA-PCL 0.7997 0.9503 0.9280 0.9956 0.7166 
PLGA-PCL 0.8797 0.9921 0.9747 0.9988 0.7842 
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